PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsBetaxolol
Betaxolol
Betaxolol, Betoptic, Kerledex (betaxolol) is a small molecule pharmaceutical. Betaxolol was first approved as Betoptic on 1985-08-30. It is used to treat hypertension and open-angle glaucoma in the USA. The pharmaceutical is active against beta-1 adrenergic receptor. In addition, it is known to target beta-2 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
cardiovascular diseasesD002318
Trade Name
FDA
EMA
Betaxolol, Betoptic (discontinued: Betaxolol, Kerlone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Betaxolol hydrochloride
Tradename
Company
Number
Date
Products
BETOPTIC SNovartisN-019845 RX1989-12-29
1 products, RLD, RS
BETOPTICSandozN-019270 RX1985-08-30
1 products, RLD, RS
Show 1 discontinued
Betaxolol hydrochloride
+
Chlorthalidone
Tradename
Company
Number
Date
Products
KERLEDEXSanofiN-019807 DISCN1992-10-30
2 products
Hide discontinued
Betaxolol hydrochloride
+
Pilocarpine hydrochloride
Tradename
Company
Number
Date
Products
BETOPTIC PILOAlcon ResearchN-020619 DISCN1997-04-17
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
betaxololANDA2023-12-20
betaxolol hydrochlorideANDA2024-04-30
betoptic2006-10-30
betoptic pilo2006-06-19
betoptic sNew Drug Application2024-07-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hypertensionEFO_0000537D006973I10
open-angle glaucomaEFO_0004190D005902H40.1
heart failureHP_0001635D006333I50
glomerulonephritisHP_0000099D005921N05
liver cirrhosisEFO_0001422D008103K74.0
nephrotic syndromeEFO_0004255D009404N04
edemaHP_0000969D004487R60.9
head and neck neoplasms—D006258—
xerostomia—D014987K11.7
angle-closure glaucoma—D015812—
Show 1 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AB: Beta blocking agents, selective
— C07AB05: Betaxolol
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01ED: Beta blocking agents, antiglaucoma preparations and miotics
— S01ED02: Betaxolol
— S01ED52: Betaxolol, combinations
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10——1——1
Ocular hypertensionD009798EFO_1001069H40.0——1——1
GlaucomaD005901EFO_0000516H40——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBetaxolol
INNbetaxolol
Description
Betaxolol is a propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment of glaucoma as well as hypertension, arrhythmias, and coronary heart disease. It is also used to reduce non-fatal cardiac events in patients with heart failure. It has a role as a beta-adrenergic antagonist, an antihypertensive agent and a sympatholytic agent.
Classification
Small molecule
Drug classbeta-blockers (propranolol type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1
Identifiers
PDB—
CAS-ID63659-18-7
RxCUI—
ChEMBL IDCHEMBL423
ChEBI ID3082
PubChem CID2369
DrugBankDB00195
UNII IDO0ZR1R6RZ2 (ChemIDplus, GSRS)
Target
Agency Approved
ADRB1
ADRB1
Organism
Homo sapiens
Gene name
ADRB1
Gene synonyms
ADRB1R, B1AR
NCBI Gene ID
153
Protein name
beta-1 adrenergic receptor
Protein synonyms
adrenergic, beta-1-, receptor, Beta-1 adrenoceptor, Beta-1 adrenoreceptor
Uniprot ID
Q9UKG8
Mouse ortholog
Adrb1 (11554)
beta-1 adrenergic receptor (P34971)
Alternate
ADRB2
ADRB2
Organism
Homo sapiens
Gene name
ADRB2
Gene synonyms
ADRB2R, B2AR
NCBI Gene ID
154
Protein name
beta-2 adrenergic receptor
Protein synonyms
adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor
Uniprot ID
Q9UMZ5
Mouse ortholog
Adrb2 (11555)
beta-2 adrenergic receptor (Q8BH38)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Betaxolol
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,677 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
963 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use